688192 迪哲医药
已收盘 07-26 15:00:00
资讯
新帖
简况
迪哲医药-U大跌5.01% 北向资金减持9.21万股
智选洞察 · 07-24
迪哲医药-U大跌5.01% 北向资金减持9.21万股
7月17日迪哲医药-U涨5.39%，鹏华医药科技股票A基金重仓该股
证券之星 · 07-17
7月17日迪哲医药-U涨5.39%，鹏华医药科技股票A基金重仓该股
国内制药企业迎来新一轮创新产品周期，创新药ETF(159992)实时成交额突破2.08亿元，百奥泰、万泰生物、迪哲医药-U领涨。
和讯网 · 07-17
国内制药企业迎来新一轮创新产品周期，创新药ETF(159992)实时成交额突破2.08亿元，百奥泰、万泰生物、迪哲医药-U领涨。
迪哲医药-U大幅上涨 获北向资金减持0.67万股
智选洞察 · 07-17
迪哲医药-U大幅上涨 获北向资金减持0.67万股
7月12日迪哲医药-U涨6.41%，鹏华医药科技股票A基金重仓该股
证券之星 · 07-12
7月12日迪哲医药-U涨6.41%，鹏华医药科技股票A基金重仓该股
迪哲医药-U07月11日获主力加仓782万元 环比增加3300.00%
自选股智能写手 · 07-11
迪哲医药-U07月11日获主力加仓782万元 环比增加3300.00%
创新药专题：2024年下半年创新药投资手册
西南证券股份有... · 07-09
创新药专题：2024年下半年创新药投资手册
迪哲医药-U07月08日遭主力抛售314万元 环比增加278.31%
自选股智能写手 · 07-08
迪哲医药-U07月08日遭主力抛售314万元 环比增加278.31%
化学制药行业盘中跳水，迪哲医药-U跌0.75%
自选股智能写手 · 07-08
化学制药行业盘中跳水，迪哲医药-U跌0.75%
广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。
和讯网 · 07-05
广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。
医药板块午后走强，科创100指数ETF(588030)涨超2%，迪哲医药-U涨超8%
和讯网 · 07-05
医药板块午后走强，科创100指数ETF(588030)涨超2%，迪哲医药-U涨超8%
今年医保药品目录调整工作正式启动，药企称政策更加规范透明
澎湃新闻 · 07-01
今年医保药品目录调整工作正式启动，药企称政策更加规范透明
6月27日迪哲医药-U跌5.08%，鹏华医药科技股票A基金重仓该股
证券之星 · 06-27
6月27日迪哲医药-U跌5.08%，鹏华医药科技股票A基金重仓该股
迪哲医药-U大跌5.05% 1家券商给予增持建议
智选洞察 · 06-27
迪哲医药-U大跌5.05% 1家券商给予增持建议
迪哲医药6月21日转融通出借成交46100股
金融界 · 06-24
迪哲医药6月21日转融通出借成交46100股
迪哲医药(688192)深度报告：国产小分子创新药领军企业
国海证券股份有... · 06-20
迪哲医药(688192)深度报告：国产小分子创新药领军企业
迪哲医药：高瑞哲（戈利昔替尼胶囊）获批上市
中国网财经 · 06-20
迪哲医药：高瑞哲（戈利昔替尼胶囊）获批上市
医药早参丨迪哲医药一肿瘤药获批，为全球首创
每日经济新闻 · 06-20
医药早参丨迪哲医药一肿瘤药获批，为全球首创
迪哲医药：目前，公司采取CMO方式委托合作方进行高瑞哲®的生产
每日经济新闻 · 06-19
迪哲医药：目前，公司采取CMO方式委托合作方进行高瑞哲®的生产
迪哲医药(688192.SH)：高瑞哲®(戈利昔替尼胶囊)获得国家药监局批准上市
智通财经 · 06-19
迪哲医药(688192.SH)：高瑞哲®(戈利昔替尼胶囊)获得国家药监局批准上市
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":36.9,"timestamp":1721977200000,"preClose":37.39,"halted":0,"volume":1270955,"delay":0,"floatShares":123000000,"shares":416000000,"eps":-2.6283,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.49,"latestTime":"07-26 15:00:00","open":37.39,"high":37.6,"low":35.68,"amount":46627800,"amplitude":0.0514,"askPrice":36.92,"askSize":2,"bidPrice":36.9,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-2.6283,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"adjPreClose":37.39,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721957400000,1721964600000],[1721970000000,1721977200000]],"highLimit":41.13,"lowLimit":33.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":415653120,"pbRate":22.02,"roa":"--","roe":"--","epsLYR":-2.72,"committee":0.184466,"marketValue":15338000000,"floatMarketCap":4542000000,"peRate":-14.039493,"changeRate":-0.0131,"turnoverRate":0.0103,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-07-29。","afterMarket":{"amount":0,"volume":0,"close":36.9,"buyVolume":200,"sellVolume":0,"time":1721979237153,"indexStatus":"已收盘 07-26 15:30:00","preClose":37.39}},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2453802894","title":"迪哲医药-U大跌5.01% 北向资金减持9.21万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453802894","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453802894?lang=zh_cn&edition=full","pubTime":"2024-07-24 14:12","pubTimestamp":1721801566,"startTime":"0","endTime":"0","summary":"07月24日，迪哲医药-U股价大幅下跌，截至14点12分，迪哲医药-U下跌5.01%，报37.13元/股，成交6014万元，换手率1.29%，振幅5.86%。资金动向截止发稿，迪哲医药-U获得主力净流入231万元，其中超大单流入180万元，大单流入50万元。北向资金方面，迪哲医药-U07月23日获得北向资金减持9.21万股，截至07月23日，北向资金当前共持有迪哲医药-U120.09万股，市值4458万元，持股占流通股比为0.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724141304aefb289a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724141304aefb289a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2452187832","title":"7月17日迪哲医药-U涨5.39%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452187832","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452187832?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:21","pubTimestamp":1721204486,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日迪哲医药-U涨5.39%，收盘报41.85元，换手率1.79%，成交量2.2万手，成交额9134.02万元。该股为创新药、医药概念热股。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.94亿元，最新净值0.9484，较上一交易日下跌0.48%，近一年下跌11.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700032596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","09939","BK1515","BK1574","159938"],"gpt_icon":0},{"id":"2452018608","title":"国内制药企业迎来新一轮创新产品周期，创新药ETF(159992)实时成交额突破2.08亿元，百奥泰、万泰生物、迪哲医药-U领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452018608","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452018608?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:29","pubTimestamp":1721194186,"startTime":"0","endTime":"0","summary":"盘面上，百奥泰领涨，万泰生物、迪哲医药-U跟涨，创新药ETF市场热度较高，过去10个交易日日均成交额达到2.22亿元。广发证券表示，国内制药企业将迎来新一轮创新产品周期。2023年CDE承办新药临床开发项目超过760项，新药首次上市申报达到110项。据此操作，风险自担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715304195cd3880&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715304195cd3880&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","603392","BK0239","515120","688192","688177"],"gpt_icon":0},{"id":"2452397750","title":"迪哲医药-U大幅上涨 获北向资金减持0.67万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452397750","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452397750?lang=zh_cn&edition=full","pubTime":"2024-07-17 10:26","pubTimestamp":1721183175,"startTime":"0","endTime":"0","summary":"07月17日，迪哲医药-U股价大幅上涨，截至10点26分，迪哲医药-U上涨5.09%，报41.73元/股，突破40元整数关口，成交3894万元，换手率0.77%，振幅5.06%。北向资金方面，迪哲医药-U07月16日获得北向资金减持0.67万股，截至07月16日，北向资金当前共持有迪哲医药-U125.57万股，市值5240万元，持股占流通股比为1.02%。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717102752af92ae64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717102752af92ae64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2450370024","title":"7月12日迪哲医药-U涨6.41%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450370024","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450370024?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:15","pubTimestamp":1720772121,"startTime":"0","endTime":"0","summary":"证券之星消息，7月12日迪哲医药-U涨6.41%，收盘报40.86元，换手率2.19%，成交量2.69万手，成交额1.09亿元。该股为创新药、医药概念热股。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.94亿元，最新净值0.9418，较上一交易日上涨2.15%，近一年下跌12.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200030549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192","BK1574","09939","BK1161","159938","BK1515"],"gpt_icon":0},{"id":"2450438297","title":"迪哲医药-U07月11日获主力加仓782万元 环比增加3300.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450438297","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450438297?lang=zh_cn&edition=full","pubTime":"2024-07-11 15:18","pubTimestamp":1720682337,"startTime":"0","endTime":"0","summary":"07月11日, 迪哲医药-U股价涨1.43%，报收38.40元，成交金额5547万元，换手率1.18%，振幅4.28%，量比0.85。迪哲医药-U今日主力资金净流入782万元，连续3日净流入，上一交易日主力净流入23万元，今日环比增加3300.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为61.54%，平均涨幅为3.67%。该股近5个交易日上涨6.90%，主力资金累计净流入541万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入526万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071115302395a4749e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071115302395a4749e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2450174090","title":"创新药专题：2024年下半年创新药投资手册","url":"https://stock-news.laohu8.com/highlight/detail?id=2450174090","media":"西南证券股份有...","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450174090?lang=zh_cn&edition=full","pubTime":"2024-07-09 18:52","pubTimestamp":1720522372,"startTime":"0","endTime":"0","summary":"对于尚未有产品商业化收入的科创板Biotech，“现金等/研发费用“比值中位数约为4.9；非科创板的A股药企基本具备较稳定的经营现金流量净额，“现金等/研发费用“比值中位数约为4.4，“经营现金流量额/研发费用”比值中位数约为1.8。部分Biotech的技术服务收入、授权收入等可以贡献较多现金，比如百利天恒BL-B01D1于2023年底和BMS的重磅合作，将获得8亿美元的首付款和最高5亿美元的或有","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407091852579596ac30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407091852579596ac30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192","600276","159992"],"gpt_icon":0},{"id":"2449740632","title":"迪哲医药-U07月08日遭主力抛售314万元 环比增加278.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449740632","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449740632?lang=zh_cn&edition=full","pubTime":"2024-07-08 15:18","pubTimestamp":1720423116,"startTime":"0","endTime":"0","summary":"07月08日, 迪哲医药-U股价跌0.49%，报收38.52元，成交金额8698万元，换手率1.82%，振幅3.77%，量比1.45。迪哲医药-U今日主力资金净流出314万元，连续3日净流出，上一交易日主力净流出83万元，今日环比增加278.31%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为53.33%，平均跌幅为1.64%。该股近5个交易日上涨7.18%，主力资金累计净流出414万元；近20日主力资金累计净流出320万元，其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708153058958ee297&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708153058958ee297&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2449308742","title":"化学制药行业盘中跳水，迪哲医药-U跌0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449308742","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449308742?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:43","pubTimestamp":1720420999,"startTime":"0","endTime":"0","summary":"07月08日，化学制药行业盘中跳水，截至14点43分，化学制药行业整体指数下跌3.01%，报8823.010点。从个股上来看，该行业的成分股中，迪哲医药-U跌0.75%，誉衡药业、ST三圣跌幅居前。从资金上来看，截止发稿，化学制药行业主力净流入为-6.59亿，其中丽珠集团受到资金热捧，主力净流入2459.30万；拉长时间线来看，该板块近20日主力资金净流入-46.22亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708144319941f4dba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708144319941f4dba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2449258347","title":"广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449258347","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449258347?lang=zh_cn&edition=full","pubTime":"2024-07-05 14:26","pubTimestamp":1720160777,"startTime":"0","endTime":"0","summary":"2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。此举标志着广东省在深化医疗保障制度改革、优化药品供应保障体系方面迈出了新的一步此措施有助于进一步规范药品市场，保障公众用药需求，提高药品可及性、促进创新药行业健康发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","159992","515120","688192","BK0216","688202","BK0239"],"gpt_icon":0},{"id":"2449525852","title":"医药板块午后走强，科创100指数ETF(588030)涨超2%，迪哲医药-U涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449525852","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449525852?lang=zh_cn&edition=full","pubTime":"2024-07-05 14:15","pubTimestamp":1720160159,"startTime":"0","endTime":"0","summary":"今日，医药板块午后走强，科创100指数医药生物成分占比高，午后快速拉升涨超2%。ETF方面，科创100指数ETF大涨超2%，成交额超3亿元，交投活跃。消息面上，7月1日，今年医保药品目录调整工作正式启动，目前医保药品目录准入申报范围主要聚焦5年内新上市药品。据此操作，风险自担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160522957b0d2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160522957b0d2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","588030","BK0239","688192"],"gpt_icon":0},{"id":"2448953990","title":"今年医保药品目录调整工作正式启动，药企称政策更加规范透明","url":"https://stock-news.laohu8.com/highlight/detail?id=2448953990","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448953990?lang=zh_cn&edition=full","pubTime":"2024-07-01 12:56","pubTimestamp":1719809760,"startTime":"0","endTime":"0","summary":"6月28日，国家医保局公布的《2024年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》，今年的工作程序仍分为准备、申报、专家评审、谈判、公布结果5个阶段，7月1日正式启动申报，争取11月份完成谈判并公布结果。每年一次的医保目录调整工作中最受关注的当属诞生过“灵魂砍价”名场面的谈判环节。吴清漪表示，对于肿瘤药而言，医保主要是解决支付性的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701125631955c43d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701125631955c43d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2446757300","title":"6月27日迪哲医药-U跌5.08%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446757300","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446757300?lang=zh_cn&edition=full","pubTime":"2024-06-27 16:22","pubTimestamp":1719476575,"startTime":"0","endTime":"0","summary":"证券之星消息，6月27日迪哲医药-U跌5.08%，收盘报37.4元，换手率1.41%，成交量1.73万手，成交额6550.64万元。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.94亿元，最新净值1.0045，较上一交易日上涨2.07%，近一年下跌3.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700029767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","688192","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2446834370","title":"迪哲医药-U大跌5.05% 1家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2446834370","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446834370?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:09","pubTimestamp":1719464968,"startTime":"0","endTime":"0","summary":"06月27日，迪哲医药-U股价大幅下跌，截至13点09分，迪哲医药-U下跌5.05%，报37.41元/股，创近2月新低，成交4602万元，换手率0.98%，振幅5.30%。资金动向截止发稿，迪哲医药-U获得主力净流出165万元，其中超大单流入154万元，大单流出318万元。北向资金方面，迪哲医药-U06月26日获得北向资金增持1.32万股，截至06月26日，北向资金当前共持有迪哲医药-U130.28万股，市值4873万元，持股占流通股比为1.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627130954aef6d983&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627130954aef6d983&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2445093335","title":"迪哲医药6月21日转融通出借成交46100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445093335","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445093335?lang=zh_cn&edition=full","pubTime":"2024-06-24 08:23","pubTimestamp":1719188636,"startTime":"0","endTime":"0","summary":"根据上交所网站显示，6月21日，迪哲医药转融通出借成交46100股，其中期限为4天的成交4400股，期限为14天的成交36500股，期限为15天的成交5200股。据了解，转融通是指证券金融公司将自有或者依法筹集的资金和证券出借给证券公司，以供其办理融资融券业务的经营活动。上交所接受借入人借入申报的时间为每个交易日 9:15 至 11:30、13:00 至 15:10。公开资料显示，迪哲医药法人代表为XIAOLIN ZHANG(张小林)，公司注册资本4.16亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406240841199f5da051&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406240841199f5da051&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2444501216","title":"迪哲医药(688192)深度报告：国产小分子创新药领军企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2444501216","media":"国海证券股份有...","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444501216?lang=zh_cn&edition=full","pubTime":"2024-06-20 20:41","pubTimestamp":1718887293,"startTime":"0","endTime":"0","summary":"国产小分子创新药领军企业：迪哲医药于2017年成立，是一家具备全球竞争力的创新型生物医药公司，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司聚焦恶性肿瘤、血液瘤等重大疾病领域，已有6款产品的多项适应症处于全球临床阶段，多款候选创新药物处于临床前研究阶段。基于我们测算，预计舒沃替尼2033年国内销售额达30亿元左右，2033年美国销售额18亿元左右。截至2023年8月31日，mPFS为5.6个月，mOS大于15个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062020413795c5a348&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062020413795c5a348&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2444254530","title":"迪哲医药：高瑞哲（戈利昔替尼胶囊）获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2444254530","media":"中国网财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444254530?lang=zh_cn&edition=full","pubTime":"2024-06-20 13:09","pubTimestamp":1718860140,"startTime":"0","endTime":"0","summary":"中国网财经6月20日讯 迪哲医药昨日宣布，高瑞哲 获得国家药监局批准上市，单药适用于既往至少接受过一线系统性治疗的复发或难治的外周T细胞淋巴瘤成人患者。单药治疗呈现出病症深度缓解、所有亚型全面获益、显度延长生存的突破性优势。迪哲医药称，公司最早发现并验证了JAK/STAT通路是治疗外周T细胞淋巴瘤的高潜力靶点，开创了全球首个通过靶向JAK/STAT通路治疗外周T细胞淋巴瘤的全新作用机制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620131131aef5c41d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620131131aef5c41d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2444282094","title":"医药早参丨迪哲医药一肿瘤药获批，为全球首创","url":"https://stock-news.laohu8.com/highlight/detail?id=2444282094","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444282094?lang=zh_cn&edition=full","pubTime":"2024-06-20 08:05","pubTimestamp":1718841905,"startTime":"0","endTime":"0","summary":"此次交易后，复星医药将持有Gland Pharma约51.83%的股份，继续保持控股地位。NO.3迪哲医药戈利昔替尼胶囊获批上市6月19日，迪哲医药公告称，公司自主研发的I类新药高瑞哲正式获得国家药品监督管理局批准，单药适用于既往至少接受过一线系统性治疗的复发或难治的外周T细胞淋巴瘤成人患者。阿斯利康表示，Truqap组合的安全性与每种药物的已知特征基本相同，没有发现新的安全信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620080512aef5b267&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620080512aef5b267&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688192","BK0239"],"gpt_icon":0},{"id":"2444215524","title":"迪哲医药：目前，公司采取CMO方式委托合作方进行高瑞哲®的生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2444215524","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444215524?lang=zh_cn&edition=full","pubTime":"2024-06-19 17:58","pubTimestamp":1718791113,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘你好，请问戈利昔替尼如果获批它的产能及销售有那些安排布局？谢谢！迪哲医药（688192.SH）6月19日在投资者互动平台表示，高瑞哲®（通用名：戈利昔替尼胶囊）已于2024年6月19日，获国家药品监督管理局批准上市，用于既往至少接受过一线系统性治疗的复发或难治的外周T细胞淋巴瘤（r/r PTCL）成人患者。公司为高瑞哲®的商业化配备了涵盖市场营销、临床推广、产品准入、医学事务、商务渠道及业务规划与运营的团队，团队核心人员兼具跨国药企和本土头部生物医药公司成功的商业化经验。目前，公司采取CMO方式委托合作方进行高瑞哲®的生产。(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191758389f4e4d82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191758389f4e4d82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2444428135","title":"迪哲医药(688192.SH)：高瑞哲®(戈利昔替尼胶囊)获得国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2444428135","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444428135?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:41","pubTimestamp":1718786507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司自主研发的I类新药高瑞哲®(通用名：戈利昔替尼胶囊)正式获得国家药品监督管理局(NMPA)批准，单药适用于既往至少接受过一线系统性治疗的复发或难治的外周T细胞淋巴瘤(r/rPTCL)成人患者。高瑞哲®是全球首个且唯一作用于JAK/STAT通路的治疗外周T细胞淋巴瘤的新药物。单药治疗呈现出病症深度缓解、所有亚型全面获益、显度延长生存的突破性优势。高瑞哲®的获批标志着公司第二款全球首创/潜在同类最佳源头创新药的上市，对公司经营发展具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","stockEarnings":[{"period":"1week","weight":-0.1164},{"period":"1month","weight":-0.0635},{"period":"3month","weight":-0.1687},{"period":"6month","weight":-0.0024},{"period":"1year","weight":0.0546},{"period":"ytd","weight":-0.2288}],"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","perCapita":"15290股","boardName":"医药制造业","registeredCapital":"41565万元","compareEarnings":[{"period":"1week","weight":-0.0307},{"period":"1month","weight":-0.0275},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1013},{"period":"ytd","weight":-0.0282}],"survey":" 迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。","serverTime":1722165581480,"listedPrice":52.58,"stockholders":"8050人(较上一季度减少4.46%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}